Ronda clínica y epidemiológica: club de revistas

  • Deibie Yesith Mendoza-Mendoza Universidad de Antioquia. Medellín. http://orcid.org/0000-0002-0214-8426
  • Camilo Andrés Restrepo-Álvarez Universidad de Antioquia. Medellín.
  • César Caraballo-Cordovez Universidad de Antioquia. Medellín.
  • José Alejandro Galeano-Toro Universidad de Antioquia. Medellín.
Palabras clave: Aneurisma Disecante, Aneurisma de la Aorta, Diálisis Renal, Enfermedad Crítica, Embolia Pulmonar, Enfermedad de la Arteria Coronaria, Fluidoterapia, Fluoroquinolonas, Infarto del Miocardio, Insuficiencia Renal, Medición de Riesgo, Mortalidad, Oxígeno

Resumen

En esta nueva edición de la Ronda Clínica y Epidemiológica, el lector podrá encontrar cuatro artículos que consideramos de especial interés para la práctica clínica actual. Abuzaid A. et al, realizan una revisión sistemática y meta-análisis que compara los desenlaces de la terapia con oxígeno vs. sin oxígeno en escenarios post-infarto agudo de miocardio. Freund Y., et al, presentan un ensayo clínico cluster de no inferioridad en el que buscan validar prospectivamente la seguridad de una estrategia basada en criterios clínicos para descartar embolismo pulmonar. Por otro lado, por medio de un diseño de cohorte retrospectiva con emparejamiento por índice de propensión, Pasternak, et al, se proponen investigar si el uso de fluoroquinolonas orales se asocia con un incremento en el riesgo de aneurisma o disección aórtica. Por último, el grupo de investigadores SMART evalúa, a través de un ensayo clínico pragmático en pacientes críticamente enfermos, el impacto de soluciones balanceadas en comparación al uso de solución salina normal en el riesgo de desarrollar eventos renales mayores.

Biografía del autor/a

Deibie Yesith Mendoza-Mendoza, Universidad de Antioquia. Medellín.
Estudiante, Facultad de Medicina.
Camilo Andrés Restrepo-Álvarez, Universidad de Antioquia. Medellín.
Estudiante, Facultad de Medicina.
César Caraballo-Cordovez, Universidad de Antioquia. Medellín.
Médico y cirujano.
José Alejandro Galeano-Toro, Universidad de Antioquia. Medellín.
Estudiante, Facultad de Medicina.

Citas

(1.) Sutton NR, Li S, Thomas L, Wang TY, de Lemos JA, Enriquez JR, et al. The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. Am Heart J. 2016 Aug;178:65-73. DOI 10.1016/j.ahj.2016.05.003.

(2.) Instituto Nacional de Salud, Observatorio Nacional de Salud. Segundo Informe ONS: Mortalidad 1998-2011 y situación de salud en los municipios de frontera terrestre en Colombia [Internet]. Bogotá: Imprenta Nacional de Colombia; 2013 [consultado 2018 Abril 5] Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INS/Segundo%20informe%20ONS.pdf

(3.) Instituto Nacional de Salud, Observatorio Nacional de Salud. Informe técnico: Carga de enfermedad por enfermedades crónicas no transmisibles y discapacidad en Colombia [Internet]. 5ª ed. Bogotá: Imprenta Nacional de Colombia; 2015 [consultado 2018 Abril 5] Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INS/informe-ons-5.pdf

(4.) Loscalzo J. Is Oxygen Therapy Beneficial in Acute Myocardial Infarction? Simple Question, Complicated Mechanism, Simple Answer. N Engl J Med. 2017 Sep;377(13):1286-1287. DOI 10.1056/NEJMe1709250.

(5.) Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation. 2015 Jun;131(24):2143-50. DOI 10.1161/CIRCULATIONAHA.114.014494.

(6.) McNulty PH, Robertson BJ, Tulli MA, Hess J, Harach LA, Scott S, et al. Effect of hyperoxia and vitamin C on coronary blood flow in patients with ischemic heart disease. J Appl Physiol (1985). 2007 May;102(5):2040-5.

(7.) Nicholson C. A systematic review of the effectiveness of oxygen in reducing acute myocardial ischaemia. J Clin Nurs. 2004 Nov;13(8):996-1007.

(8.) Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. N Engl J Med. 2017 Sep;377(13):1240-9. DOI 10.1056/NEJMoa1706222.

(9.) Freund Y, Cachanado M, Aubry A, Orsini C, Raynal PA, Féral-Pierssens AL, et al. Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial. JAMA. 2018 Feb;319(6):559-66. DOI 10.1001/jama.2017.21904.

(10.) Kline JA. Utility of a Clinical Prediction Rule to Exclude Pulmonary Embolism Among Low-Risk Emergency Department Patients: Reason to PERC Up. JAMA. 2018 Feb;319(6):551-3. DOI 10.1001/jama.2017.21901.

(11.) Thompson TB, Kabrhel C, Pena C. Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism [Internet]. Walthman (MA): UpToDate; 2018 [consultado Abril 10 de 2018]. Available from: https://www.uptodate.com/contents/clinical-presentation-evaluation-and-diagnosis-of-the-nonpregnant-adultwith-suspected-acute-pulmonary-embolism

(12.) Raja AS, Greenberg JO, Qaseem A, Denberg TD, Fitterman N, Schuur JD, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2015 Nov;163(9):701-11. DOI 10.7326/M14-1772.

(13.) Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov;35(43):3033-69, 3069a-3069k. DOI 10.1093/eurheartj/ehu283. Erratum in: Eur Heart J. 2015 Oct;36(39):2666. Eur Heart J. 2015 Oct;36(39):2642.

(14.) Penaloza A, Verschuren F, Meyer G, Quentin-Georget S, Soulie C, Thys F, et al. Comparison of the unstructured clinician gestalt, the wells score, and the revised Geneva score to estimate pretest probability for suspected pulmonary embolism. Ann Emerg Med. 2013 Aug;62(2):117-124.e2. DOI 10.1016/j.annemergmed.2012.11.002.

(15.) Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA, Plewa MC, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008 May;6(5):772-80. DOI 10.1111/j.1538-7836.2008.02944.x.

(16.) Wolf SJ, McCubbin TR, Nordenholz KE, Naviaux NW, Haukoos JS. Assessment of the pulmonary embolism rule-out criteria rule for evaluation of suspected pulmonary embolism in the emergency department. Am J Emerg Med. 2008 Feb;26(2):181-5. DOI 10.1016/j.ajem.2007.04.026.

(17.) Hugli O, Righini M, Le Gal G, Roy PM, Sanchez O, Verschuren F, et al. The pulmonary embolism rule-out criteria (PERC) rule does not safely exclude pulmonary embolism. J Thromb Haemost. 2011 Feb;9(2):300-4. DOI 10.1111/j.1538-7836.2010.04147.x. Erratum in: J Thromb Haemost. 2012 Apr;10(4):740.

(18.) Sousa J, Alves G, Fortuna A, Falcão A. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf. 2014;9(2):89-105.

(19.) Food and Drug Administration. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection [Internet]. [cited 2018 Apr 5]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafet/UCM365078.pdf142

(20.) Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol. 2014 Apr;24(4):279-85. DOI 10.1016/j.annepidem.2013.12.009.

(21.) Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology. 2014 Sep;83(14):1261-3. DOI 10.1212/WNL.0000000000000846.

(22.) Tibaduiza García MF, Caraballo Cordovez C, Hincapié Osorno C, Garcés Rodríguez DJ, Jaimes Barragán F. Ronda clínica y epidemiológica: una revisión de cuatro artículos relevantes para la práctica clínica. Iatreia. 2015 Abr-Jun;28(2):207-213. DOI 10.17533/udea.iatreia.v28n2a12.

(23.) Food and Drugs Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together [Internet]. 2016. [cited 2018 Apr 7]. Available from: https://www.fda.gov/drugs/drugsafety/ucm500143.htm

(24.) Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015 Nov;5(11):e010077. DOI 10.1136/bmjopen-2015-010077.

(25.) Lee CC, Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, et al. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med. 2015 Nov;175(11):1839-47. DOI 10.1001/jamainternmed.2015.5389.

(26.) Food and Drugs Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects [Internet]. 2017. [Cited 2018 Apr 7] Available from: https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

(27.) Che-Kim T. Re: Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study [letter to the editor] [internet]. March 2018 [cited 2018 Apr 5]. Available from: https://www.bmj.com/content/360/bmj.k678/rr-2

(28.) Imfeld S. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study [letter to the editor] [internet]. March 2018 [cited 2018 Apr 5]. Avaliable from: https://www.bmj.com/content/360/bmj.k678/rr-1

(29.) Semler MW, Self WH, Wang L, Byrne DW, Wanderer JP, Ehrenfeld JM, et al. Balanced crystalloids versus saline in the intensive care unit: study protocol for a cluster-randomized, multiple-crossover trial. Trials. 2017 Mar;18(1):129. DOI 10.1186/s13063-017-1871-1.

(30.) Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D, et al. The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med. 2011 Nov;39(11):2419-24. DOI 10.1097/CCM.0b013e31822571e5.

(31.) Nieto-Rios JF, Bello-Márquez DC. Integración en la interpretación de los electrolitos y los gases sanguíneos. En: Enfoques Prácticos en Medicina Interna. Medellín: Universidad Pontificia Bolivariana; 2017. p. 53-72.

(32.) Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct;308(15):1566-72. DOI 10.1001/jama.2012.13356.

(33.) Gómez A. Homeostasis del hidrógeno: una aproximación basada en la teoría de Stewart. En: Ordoñez CF, Buitrago R, editors. Cuidado Intensivo y Trauma. 2a ed. Bogotá: Distribuna; 2009. p. 85-102.

(34.) Rimes-Stigare C, Frumento P, Bottai M, Mårtensson J, Martling CR, Bell M. Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease. Crit Care. 2015 Nov;19:383. DOI 10.1186/s13054-015-1101-8.

(35.) Dennis RJ, Pérez A, Rowan K, Londoño D, Metcalfe A, Gómez C, et al. Factores asociados con la mortalidad hospitalaria en pacientes admitidos en cuidados intensivos en Colombia. AB. 2002;38(3):117-22. DOI 10.1016/S0300-2896(02)75168-5.

(36.) Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M, et al. Brazilian Sepsis Epidemiological Study (BASES study). Crit Care. 2004 Aug;8(4):R251-60.

(37.) Rada G, Roa M. Qué son y cómo se interpretan los outcomes compuestos. Rev Méd Chile. 2009 Nov;137(11):1523-6. DOI 10.4067/S0034-98872009001100019.

(38.) Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun;158(11):825-30. DOI 10.7326/0003-4819-158-11-201306040-00007.

(39.) Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017 Apr;13(4):241-257. DOI 10.1038/nrneph.2017.2.

(40.) Walsh M, Perkovic V, Manns B, Srinathan S, Meaden MO, Devereaux P, et al. Therapy (Randomized Trials). In: Guyatt G, Rennie D, Meaden MO, Cook DJ, editors. Users’ Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3th ed. New York: McGraw Hill Education & The JAMA Network; 2015. p. 59-74.

(41.) Myburgh J. Patient-Centered Outcomes and Resuscitation Fluids. N Engl J Med. 2018 Mar;378(9):862-3. DOI 10.1056/NEJMe1800449.

Publicado
2018-07-01
Sección
Actualización crítica